Placenta Accreta Spectrum Disorders,Previous Cesarean SectionNCT06021964
Prospective Cohort Observational Study of Placenta Accreta Spectrum Disorders
An observational study of Placenta Accreta Spectrum Disorders,Previous Cesarean Section, run by Guangzhou Medical University at 1 site in China.
Trial summary
The incidence of placenta accreta spectrum disorders has shown an increasing trend worldwide due to the increase of cesarean section rate. Research on the outcomes of placenta accreta spectrum disorders primarily relies on retrospective analysis. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Placenta Accreta Spectrum Disorders,Previous Cesarean Section
- How many people
- 1,000 participants
- Where
- 1 siteChina
- Study dates
- 28 Aug 2023to 7 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Study population: Pregnant women aged 18-45 who at least had one previous cesarean section
Who may be able to join
- Pregnant women aged 18-45;
- at least one previous cesarean section ,regular antenatal examination and plan to give birth at research center
- sign informed consent
Who cannot join
- Irregular antenatal examination; Twins; Autoimmune diseases; Prepregnancy hypertension; Prepregnancy diabetes mellitus; Inheritance Sexual diseases; tumor; Abnormal liver and kidney function in early pregnancy
Trial locations and contacts
1 site in 1 country.
China1 site
Department of Obstetrics and Gynecology, Key Laboratory for Major Obstetric Diseases of Guangdong Province, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology，The Third Affiliated Hospital of Guangzhou Medical University
Guangzhou, 510150
About this study
The incidence of placenta accreta spectrum disorders has shown an increasing trend worldwide due to the increase of cesarean section rate. Research on the outcomes of placenta accreta spectrum disorders primarily relies on retrospective analysis. The aim of this study was to establish a prospective, multicenter cohort in China in order to conduct further investigations on the clinical features, predictive capabilities, diagnostic methods, and pathogenesis of placenta accreta spectrum disorders.
- Keywords
- placenta accreta spectrum disorders；Previous cesarean section
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of placenta accreta spectrum disorders
Measured: baseline
Secondary outcomes (5)
Preterm delivery Preterm delivery
Measured: baseline
Blood lost during delivery
Measured: baseline
Blood loss in the first 24 hours of delivery
Measured: baseline
hysterectomy
Measured: baseline
Blood transfusion
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2023
- Study start28 Aug 2023 (estimated)
- Primary completion30 Nov 2025 (estimated)
- Study completion7 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Placenta Accreta Spectrum Disorders,Previous Cesarean SectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Guangzhou Medical University
- Sponsor type
- University, hospital or other
- Collaborators
- Peking University Third Hospital, Nanfang Hospital, Southern Medical University, Peking Union Medical College Hospital, TONGJI MEDICAL COLLEGE OF HUST, First Affiliated Hospital of Chongqing Medical University, West China Second University Hospital, Peking University First Hospital
- Responsible party
- Principal investigator, Dunjin Chen, Guangzhou Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06021964
- Sponsor's protocol ID
- 2022YFC2704501
- Status last verified
- Aug 2023
- First submitted
- 27 Aug 2023
- Last updated
- 1 Sep 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Cohort Observational Study of Placenta Accreta Spectrum Disorders
- ClinicalTrials.gov ID
- NCT06021964
- Acronym / sponsor ID
- 2022YFC2704501
- Keywords
- placenta accreta spectrum disorders；Previous cesarean section
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Guangzhou Medical UniversityUniversity, hospital or other
- Collaborators
- Peking University Third Hospital, Nanfang Hospital, Southern Medical University, Peking Union Medical College Hospital, TONGJI MEDICAL COLLEGE OF HUST, First Affiliated Hospital of Chongqing Medical University, West China Second University Hospital, Peking University First Hospital
- Study start
- 28 Aug 2023 (estimated)
- Primary completion
- 30 Nov 2025 (estimated)
- Study completion
- 7 Dec 2025 (estimated)
- First posted
- 1 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The incidence of placenta accreta spectrum disorders has shown an increasing trend worldwide due to the increase of cesarean section rate. Research on the outcomes of placenta accreta spectrum disorders primarily relies on retrospective analysis. The aim of this study was to establish a prospective, multicenter cohort in China in order to conduct further investigations on the clinical features, predictive capabilities, diagnostic methods, and pathogenesis of placenta accreta spectrum disorders.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Pregnant women aged 18-45 who at least had one previous cesarean section
Key inclusion criteria (3 listed)
- Pregnant women aged 18-45;
- at least one previous cesarean section ,regular antenatal examination and plan to give birth at research center
- sign informed consent
Key exclusion criteria (1 listed)
- Irregular antenatal examination; Twins; Autoimmune diseases; Prepregnancy hypertension; Prepregnancy diabetes mellitus; Inheritance Sexual diseases; tumor; Abnormal liver and kidney function in early pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Incidence of placenta accreta spectrum disorders
Time frame: baseline
5 secondary outcomes
Preterm delivery Preterm delivery
Time frame: baseline
Blood lost during delivery
Time frame: baseline
Blood loss in the first 24 hours of delivery
Time frame: baseline
hysterectomy
Time frame: baseline
Blood transfusion
Time frame: baseline
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Placenta Accreta Spectrum Disorders,Previous Cesarean Section
Not yet recruitingObservational study
Hematological and Coagulation Markers in Predicting Placenta Accreta Spectrum in Placenta Previa
Placenta Accreta Spectrum, Placenta Previa
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Placenta Accreta Spectrum Disorders,Previous Cesarean Section, run by Guangzhou Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of placenta accreta spectrum disorders (time frame: baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2023.